CurrentBlue Cross Blue Shield - TexasPolicy CPCP020

Drug Testing Clinical Payment and Coding Policy

Defines reimbursement, coding, documentation, and CLIA requirements for presumptive and definitive drug testing claims for Blue Cross and Blue Shield of Texas; applies to providers and laboratories submitting claims to the plan.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyDrug Testing Clinical Payment and Coding Policy

Policy CodePolicy CPCP020

Change TypeMinor or no material change

Effective DateFeb 13, 2025

Next Review DateN/A

Key ActionSubmit medical record documentation and an appropriately documented order with claims for presumptive (CPT 80305-80307) and definitive (G0480-G0483, G0659) testing; ensure CLIA certification and bill only services you perform.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

80305-80307Presumptive CPTs considered

G0480-G0483, G0659Definitive G-codes considered

One per dayDefinitive billing limit

IncludedValidity testing

RequiredCLIA

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Restrictions

Coverage criteria and restrictions

Reimbursement is conditional on coding, documentation, CLIA certification, and clinical necessity as detailed below.

ALL of the following

Correct CPT/HCPCS coding is submitted: presumptive testing CPT 80305-80307; definitive testing HCPCS G0480, G0481, G0482, G0483, G0659.
Providers may only bill for services they perform; pass-through billing for services performed by a third party is not permitted.
Reimbursement is subject to member benefit and eligibility, applicable medical policy, and provider contract language.

ALL of the following

A written order signed and dated by the ordering clinician is required and must indicate each specific drug or drug class being tested; reference to a standard order or 'custom panel' is not acceptable.
Medical record documentation must support medical necessity and be patient-specific (relevant history, physical exam, diagnostic results, and a supporting diagnosis).
The laboratory requisition must include patient identity, ordering provider identity (name, credentials, NPI), legible physician signature, sample type, collection date/time, collector identity, and date/time received by the laboratory.
Lab results must include the performing entity identification (name, address, CLIA number), patient identifiers, ordering provider name and NPI, collection/receipt/report dates, and complete test results including validity testing if performed.

ALL of the following

Providers performing testing must have appropriate CLIA certification for the type of testing performed.
Independent laboratory claims should be submitted to the Blue Cross and Blue Shield plan in the state where the referring/ordering provider is located.

ALL of the following

Definitive quantitative testing should follow MED207.154 and is appropriate only when documentation supports the rationale (e.g., unexpected presumptive result or lack of an available presumptive test for a specific opioid).
Review of presumptive results by the treating physician should occur before ordering definitive testing; if definitive testing is ordered without prior presumptive testing, the medical record must justify the test.

ALL of the following

Custom panels, reflex/automatic testing, standing orders, and routine screening without individualized patient assessment are not reimbursable.
Panel testing is restricted to panels published in the current CPT manual; 'custom' panels are not reimbursable.
Specimen validity testing is included in the base definitive and presumptive codes and may not be billed separately; abnormal validity testing may make subsequent testing of that sample not reimbursable.

ALL of the following

Claims are subject to code edits and review against benefit coverage, medical policy, and provider contract terms; claims with insufficient documentation will be denied.
The provider submitting the claim is responsible for providing, upon request, sufficient documentation (including orders and medical records) to support all services on the claim form; complying with a documentation request does not guarantee reimbursement.

ALL of the following

This policy does not address state, federally regulated, or legally mandated drug testing (e.g., court-ordered screening or forensic examinations).

ALL of the following

Urine is the preferred matrix but other matrices (blood, oral fluid, hair, sweat, exhaled breath) may be medically necessary when urine cannot be collected or when clinically indicated; the clinician's documentation must support the chosen matrix.

Coding and Billing

Presumptive (qualitative) drug screeningCPTCovered

80305	Drug test presumptive, direct optical observation only
80306	Drug test presumptive, instrument-assisted direct optical observation
80307	Drug test presumptive, instrumented chemistry analyzers

Definitive (quantitative) drug testingHCPCSCovered

G0480	Definitive drug test, 1-7 drug classes, includes specimen validity testing
G0481	Definitive drug test, 8-14 drug classes, includes specimen validity testing
G0482	Definitive drug test, 15-21 drug classes, includes specimen validity testing
G0483	Definitive drug test, 22+ drug classes, includes specimen validity testing
G0659	Definitive drug test simple, any number of classes, without method- or drug-specific calibration

Definitive code billing limit

Billing limitOnly one definitive G-code (G0480‑G0483 or G0659) may be billed per date of service.

Applies toAll definitive HCPCS G‑codes listed in policy (G0480, G0481, G0482, G0483, G0659).

RationaleGuidelines for each definitive code state that only one definitive G code may be billed per date of service.

Validity testing billing rule

Inclusion in base codeSpecimen validity testing is included in the presumptive (CPT 80305‑80307) and definitive (G0480‑G0483, G0659) base codes and may not be billed separately.

Abnormal validity result

Claims Submission and Documentation Requirements

Documentation Required

Claims Submission and Documentation Requirements

Reimbursement under this policy is subject to proper medical record documentation, a signed order that supports the specific test(s) ordered, correct CPT/HCPCS coding, member eligibility, and applicable medical policy. Claims accompanied by medical records that do not meet the documentation and order requirements will not be reimbursed. This policy does not apply to state, federally regulated, or legally mandated drug testing (for example, court-ordered drug screening or forensic examinations).

Medical record documentation must include the patient's relevant history, physical examination, diagnostic test(s) and/or procedure results, and a diagnosis consistent with those findings and/or test results.
Each drug or drug class being tested for must be indicated by the ordering clinician in a written order and documented in the patient’s medical record.
Orders must be signed and dated by the ordering health care professional.
Panel testing is restricted to panels published in the current CPT manual; custom panels are not reimbursable.
Routine screenings or panel testing performed as part of a clinician’s protocol without documented individual patient assessment are not reimbursable.
Standing orders that are non‑individualized and not used in management of a specific patient are not reimbursable.
Reflex (automatic) and validity testing used internally to affirm accuracy/validity are not separately reimbursable when they are part of internal laboratory processes.

Definitions

Quantitative (definitive) testing

DefinitionQuantitative (definitive) testing identifies individual drugs and distinguishes structural isomers using methods such as GC/MS or LC/MS; it provides definitive, often quantitative, identification.

Clinical useOrdered after review of presumptive results or when documentation supports the need (e.g., unexpected qualitative result or lack of an available presumptive test).

Specimen typesMay be performed on urine, blood, oral fluid, sweat, hair or exhaled breath; urine is the preferred matrix but others are used when clinically necessary.

Presumptive (qualitative) testing

DefinitionPresumptive (qualitative) testing are initial drug class screening tests (CPT 80305, 80306, 80307) performed by direct optical observation or instrument methods and include validity testing when performed.